CL2010001485A1 - Procedimiento de preparacion de un compuesto derivado de b-d-glucopiranosa espirocondensado con un heterociclo; compuestos intermediarios; forma cristalina y cocristales de 1,1-anhidro -1-c-[5-(4-etifenil) metil- 2( hidroximetil)fenil]-b-d-glucopiranosa, util para prevenir o tratar la diabetes. - Google Patents

Procedimiento de preparacion de un compuesto derivado de b-d-glucopiranosa espirocondensado con un heterociclo; compuestos intermediarios; forma cristalina y cocristales de 1,1-anhidro -1-c-[5-(4-etifenil) metil- 2( hidroximetil)fenil]-b-d-glucopiranosa, util para prevenir o tratar la diabetes.

Info

Publication number
CL2010001485A1
CL2010001485A1 CL2010001485A CL2010001485A CL2010001485A1 CL 2010001485 A1 CL2010001485 A1 CL 2010001485A1 CL 2010001485 A CL2010001485 A CL 2010001485A CL 2010001485 A CL2010001485 A CL 2010001485A CL 2010001485 A1 CL2010001485 A1 CL 2010001485A1
Authority
CL
Chile
Prior art keywords
glucopyranoside
preparing
ethiphenyl
spirocondensed
heterocycle
Prior art date
Application number
CL2010001485A
Other languages
English (en)
Inventor
Murakata Masatoshi
Ikeda Takuma
Kimura Nobuaki
Kawase Akira
Nagase Masahiro
Yamamoto Keisuke
Takata Noriyuki
Yoshizaki Shinichi
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41434188&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2010001485(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of CL2010001485A1 publication Critical patent/CL2010001485A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/01—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing oxygen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04—Carbocyclic radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H23/00—Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Procedimiento para preparar compuestos derivados de espirocetal, compuestos intermediarios y compuestos cristalinos derivados de espirocetal.
CL2010001485A 2008-06-20 2010-12-20 Procedimiento de preparacion de un compuesto derivado de b-d-glucopiranosa espirocondensado con un heterociclo; compuestos intermediarios; forma cristalina y cocristales de 1,1-anhidro -1-c-[5-(4-etifenil) metil- 2( hidroximetil)fenil]-b-d-glucopiranosa, util para prevenir o tratar la diabetes. CL2010001485A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2008162073 2008-06-20

Publications (1)

Publication Number Publication Date
CL2010001485A1 true CL2010001485A1 (es) 2011-09-16

Family

ID=41434188

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2010001485A CL2010001485A1 (es) 2008-06-20 2010-12-20 Procedimiento de preparacion de un compuesto derivado de b-d-glucopiranosa espirocondensado con un heterociclo; compuestos intermediarios; forma cristalina y cocristales de 1,1-anhidro -1-c-[5-(4-etifenil) metil- 2( hidroximetil)fenil]-b-d-glucopiranosa, util para prevenir o tratar la diabetes.

Country Status (24)

Country Link
US (2) US8569520B2 (es)
EP (3) EP3170834B8 (es)
JP (2) JP4823385B2 (es)
KR (1) KR101856784B1 (es)
CN (1) CN102046645B (es)
AR (1) AR072211A1 (es)
AU (1) AU2009261129A1 (es)
CA (1) CA2727923A1 (es)
CL (1) CL2010001485A1 (es)
CO (1) CO6351798A2 (es)
CR (1) CR20110033A (es)
EC (1) ECSP11010773A (es)
ES (1) ES2907611T3 (es)
IL (1) IL210098A0 (es)
MA (1) MA32530B1 (es)
MX (1) MX2010014023A (es)
NZ (1) NZ589961A (es)
PE (1) PE20110115A1 (es)
PL (1) PL3170834T3 (es)
RU (1) RU2011101972A (es)
SG (1) SG193795A1 (es)
TW (1) TW201011043A (es)
WO (1) WO2009154276A1 (es)
ZA (1) ZA201100016B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5711669B2 (ja) * 2009-12-18 2015-05-07 中外製薬株式会社 スピロケタール誘導体の製造方法
WO2012115249A1 (ja) * 2011-02-25 2012-08-30 中外製薬株式会社 スピロケタール誘導体の結晶
CN104039785A (zh) * 2011-10-06 2014-09-10 拜耳知识产权有限责任公司 作为杀真菌剂的杂环基吡(嘧)啶基吡唑
AU2014370847B2 (en) 2013-12-27 2020-02-20 Chugai Seiyaku Kabushiki Kaisha Solid preparations containing tofogliflozin and process of producing the same
CN106188190B (zh) * 2016-07-28 2020-08-25 迪嘉药业集团有限公司 一种托格列净一水合物的制备方法
BR112019005930A2 (pt) 2016-10-19 2019-06-11 Boehringer Ingelheim Int combinações compreendendo um inibidor de ssao/vap-1 e um inibidor de sglt2, e usos das mesmas
CN108640958B (zh) * 2017-05-05 2021-03-30 镇江圣安医药有限公司 异苯并呋喃衍生物、其药物组合物和制剂以及用途
US20210113561A1 (en) 2018-04-17 2021-04-22 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
DK3873600T5 (da) 2018-10-29 2024-03-18 Boehringer Ingelheim Int Pyridinylsulfonamidderivater, farmaceutiske sammensætninger og anvendelser deraf
US12213970B2 (en) 2018-10-29 2025-02-04 Boehringer Ingelheim International Gmbh Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL63968A (en) 1980-10-01 1985-10-31 Glaxo Group Ltd Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it
HU196775B (en) * 1986-08-05 1989-01-30 Richter Gedeon Vegyeszet Process for production of morfologically unique new modifications of famotidin and medical compositions containing such substances
PT98344B (pt) 1991-07-17 1999-04-30 Lneti Lab Nac De Eng Tec Ind D Processo para a obtencao de espirocetais labdanicos do tipo ambar cinzento
GB9426103D0 (en) 1994-12-23 1995-02-22 Merck Sharp & Dohme Therapeutic agents
JP2000044534A (ja) 1998-07-28 2000-02-15 Mitsui Chemicals Inc Ｎ保護基アミノ酸の製造法
WO2001057046A1 (en) 2000-02-02 2001-08-09 Banyu Pharmaceutical Co., Ltd. Method of converting functional group through halogen-metal exchange reaction
JP3849024B2 (ja) 2003-03-26 2006-11-22 国立大学法人 東京大学 有機亜鉛錯体およびその製造方法
TW200637869A (en) 2005-01-28 2006-11-01 Chugai Pharmaceutical Co Ltd The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
CN101389632B (zh) 2005-12-23 2013-02-06 生态生物有限公司 螺缩酮
JP5230613B2 (ja) 2006-05-23 2013-07-10 テラコス・インコーポレイテッド グルコース輸送体阻害剤およびその使用方法
TWI403516B (zh) 2006-07-27 2013-08-01 Chugai Pharmaceutical Co Ltd To replace spirocyclic alcohol derivatives, and its use as a therapeutic agent for diabetes

Also Published As

Publication number Publication date
CN102046645A (zh) 2011-05-04
IL210098A0 (en) 2011-02-28
ZA201100016B (en) 2012-03-28
MX2010014023A (es) 2011-02-15
PE20110115A1 (es) 2011-02-14
ECSP11010773A (es) 2011-02-28
KR101856784B1 (ko) 2018-05-10
ES2907611T3 (es) 2022-04-25
HK1154589A1 (en) 2012-04-27
CR20110033A (es) 2011-02-16
CO6351798A2 (es) 2011-12-20
TW201011043A (en) 2010-03-16
EP3170834B8 (en) 2022-03-23
JP5485237B2 (ja) 2014-05-07
AU2009261129A1 (en) 2009-12-23
EP2308886A1 (en) 2011-04-13
AR072211A1 (es) 2010-08-11
PL3170834T3 (pl) 2022-05-02
SG193795A1 (en) 2013-10-30
US20110306778A1 (en) 2011-12-15
EP4036100A1 (en) 2022-08-03
JP4823385B2 (ja) 2011-11-24
RU2011101972A (ru) 2012-07-27
KR20110020909A (ko) 2011-03-03
JP2012001554A (ja) 2012-01-05
US20140024817A1 (en) 2014-01-23
CN102046645B (zh) 2015-04-01
CA2727923A1 (en) 2009-12-23
EP3170834A1 (en) 2017-05-24
US9163051B2 (en) 2015-10-20
EP2308886B1 (en) 2016-12-07
NZ589961A (en) 2012-12-21
JPWO2009154276A1 (ja) 2011-12-01
US8569520B2 (en) 2013-10-29
WO2009154276A1 (ja) 2009-12-23
EP3170834B1 (en) 2022-02-09
MA32530B1 (fr) 2011-08-01
EP2308886A4 (en) 2013-04-03

Similar Documents

Publication Publication Date Title
CL2010001485A1 (es) Procedimiento de preparacion de un compuesto derivado de b-d-glucopiranosa espirocondensado con un heterociclo; compuestos intermediarios; forma cristalina y cocristales de 1,1-anhidro -1-c-[5-(4-etifenil) metil- 2( hidroximetil)fenil]-b-d-glucopiranosa, util para prevenir o tratar la diabetes.
AR108259A2 (es) Compuestos para el control de nematodos de plantas
ATE555105T1 (de) Heterocyclische fxr-bindende verbindungen
AR094588A2 (es) Proceso de obtención de un compuesto derivado de benzimidazol y composición farmacéutica
CL2008003529A1 (es) Compuestos derivados de acido-[(4,5-disustituido)-4h-1,2,4-triazol-3-il o (2,4-disustituido)-1,3-imidazol-2-il]carboxilico, moduladores de los niveles de acido urico sanguineos, utiles para el tratamiento de la gota.
ECSP088286A (es) COMPUESTOS DE AMINO-5-[4-(DIFLUOROMETOXI)FENIL]-5-FENILIMIDAZOLONA PARA LA INHIBICIÓN DE LA ß-SECRETASA
MX2014000359A (es) Metodos plaguicidas que utilizan compuestos de 3 - piridin tiazol sustituido y derivados para combatir las plagas de animales ii.
EA201071032A1 (ru) Гетероциклическое соединение
NO20090235L (no) Kondenserte sykliske forbindelser
CL2007002268A1 (es) Procedimiento de preparacion de compuestos derivados de ciclopropilamina opticamente activo; compuesto intermediario derivado de 2-aril ciclopropancarboxamida opticamente activo.
PE20161396A1 (es) Compuesto heterociclico
EA201400231A1 (ru) Фунгицидные замещенные 1-{2-[2-галоген-4-(4-галогенфенокси)фенил]-2-алкокси-2-алкинил/алкенилэтил}-1н-[1,2,4]триазольные соединения
CL2012000929A1 (es) Proceso para la obtencion de derivados de glucosa por acoplamiento entre un compuesto organometalico de zinc y un derivado de glucosa protegido y su posterior desproteccion.
TW200716563A (en) Process for the synthesis of organic compounds
WO2011157733A3 (en) Use of substituted heterocyclic compounds to control sea lice on fish
CL2011001295A1 (es) Compuestos derivados de 1h-pirazol-4-carboxamida; metodo de control o prevencion de una infestacion de plantas utiles por microorganismos fitopatogenos; composicion pesticida que comprende a dichos compuestos.
MX2012005358A (es) Procedimiento para la preparacion de etexilato de dabigatran.
CR20110432A (es) Pirimidinas fusionadas
MX2009009699A (es) Compuestos amino-5-[4-(difluorometoxi)fenil sustituidos]-5-fenilim idazolona como inhibidores de beta-secretasa.
CL2011000242A1 (es) Uso de compuestos derivados de fenilaminopirimidina para tratar talasemia alfa, delta y anemia celular falciforme, talasemia mayor, talasemia menor, talasemia e-beta o talasemia beta falciforme, o para mejorar o retrasar los sintomas de las mismas y uso de un compuesto especifico para tratar la talasemia.
PE20142282A1 (es) Nuevos derivados de aril-quinolina
MX2009003257A (es) Procedimiento para la sintesis de derivados de fenoxi diaminopirimidina.
AR082870A1 (es) Derivados de tetrazoles y sus composiciones para su uso como funguicida o plaguicida
AR064658A1 (es) Proceso para preparar duloxetina y sus compuestos relacionados, asi como tambien intermediarios utiles en la misma
EA201200868A1 (ru) Ингибиторы диацилглицеролацилтрансферазы